AstraZeneca

2024 - 5 - 20

AstraZeneca's Billion-Dollar Cancer Drug Plant to Revolutionize Treatment

astrazeneca singapore ADCs - AstraZeneca - Cancer Treatment - Singapore - astrazeneca singapore

AstraZeneca plans to build a groundbreaking $1.5 billion manufacturing facility in Singapore to produce cutting-edge cancer-killing drugs, revolutionizing treatment options.

AstraZeneca, the pharmaceutical giant, is making waves with its ambitious plans to construct a state-of-the-art $1.5 billion manufacturing facility in Singapore. The facility will focus on producing antibody-drug conjugates (ADCs), a promising category of cancer-killing drugs designed to target cancer cells while sparing healthy tissue. ADCs deliver toxic drugs directly to the cancer cells, offering a more targeted and effective treatment approach.

The move signifies AstraZeneca's commitment to advancing cancer treatment by investing in innovative manufacturing capabilities. With an industry-leading portfolio of cancer medicines, including ADCs like Enhertu, the company aims to strengthen the global supply of these life-saving drugs.

In a strategic shift, AstraZeneca's investment in Singapore emphasizes the importance of the Asia-Pacific region in the pharmaceutical industry's growth. By establishing its first fully dedicated ADC manufacturing facility in Singapore, the company is poised to revolutionize cancer treatment and lead the way in groundbreaking therapies.

As AstraZeneca continues to expand its manufacturing footprint, the $1.5 billion investment underscores the company's dedication to advancing cancer care and improving patient outcomes. The cutting-edge facility in Singapore represents a significant milestone in the pharmaceutical industry's efforts to develop more targeted and effective treatments for cancer patients.

Post cover
Image courtesy of "The Business Times"

Ryanair sees flat to modestly higher summer fares after record ... (The Business Times)

RYANAIR on Monday (May 20) posted a 34 per cent year-on-year increase in annual profit to a record 1.92 billion euros (S$2.8 billion), and expressed ...

Post cover
Image courtesy of "CNA"

AstraZeneca to build US$1.5 billion cancer drug manufacturing plant ... (CNA)

AstraZeneca plans to build a US$1.5 billion manufacturing facility in Singapore to produce antibody-drug conjugates (ADCs) and targeted cancer therapies, ...

Post cover
Image courtesy of "Reuters"

AstraZeneca to build $1.5-bln cancer drug plant in Singapore (Reuters)

AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of cancer-killing drugs called antibody-drug ...

Post cover
Image courtesy of "Financial Times"

AstraZeneca to build $1.5bn manufacturing site in Singapore (Financial Times)

ADCs deliver toxic drugs directly to cancer cells, avoiding damage to surrounding healthy tissue. AstraZeneca has a portfolio of the drugs, including Enhertu, ...

Post cover
Image courtesy of "British Chamber Of Commerce Singapore"

AstraZeneca plans $1.5 billion manufacturing facility for antibody ... (British Chamber Of Commerce Singapore)

“AstraZeneca has built an industry-leading portfolio of cancer medicines including antibody drug conjugates which have shown enormous potential to replace ...

Post cover
Image courtesy of "BioProcess Insider"

AstraZeneca to build $1.5bn ADC site in Singapore (BioProcess Insider)

AstraZeneca has laid out plans to construct its first fully dedicated antibody-drug conjugate (ADC) manufacturing facility in Singapore.

Post cover
Image courtesy of "TIME"

AstraZeneca Plans $1.5 Billion Factory in Singapore as Drug ... (TIME)

AstraZeneca Plc plans to build a $1.5 billion manufacturing facility in Singapore to make antibody-drug conjugates as the U.K. drugmaker pushes to beef up ...

Post cover
Image courtesy of "The Straits Times"

Pharma giant AstraZeneca to build $2 billion manufacturing facility ... (The Straits Times)

The company's new facility in Singapore will be designed for manufacturing antibody drug conjugates (ADCs) to enhance the global supply of its ADC portfolio, it ...

Post cover
Image courtesy of "Pharmaceutical Technology Magazine"

AstraZeneca Plans $1.5 Billion ADCs Facility in Singapore (Pharmaceutical Technology Magazine)

The new facility will be the company's first to offer full manufacturing processing for antibody drug conjugates.

Post cover
Image courtesy of "The Business Times"

AstraZeneca to build US$1.5 billion manufacturing plant in Singapore (The Business Times)

ASTRAZENECA is planning to build a US$1.5 billion facility in Singapore to manufacture antibody drug conjugates (ADCs), or treatments that enable precision ...

Post cover
Image courtesy of "The Business Times"

Apple supplier Foxconn among firms asked to cut power use in ... (The Business Times)

VIETNAMESE officials have called on Apple supplier Foxconn to voluntarily reduce power use by 30 per cent at its assembly plants in the north of the country ...

AstraZeneca sets ambition to deliver $80 billion Total Revenue by ... (AstraZeneca)

Launch of 20 new medicines expected by 2030. Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios

Post cover
Image courtesy of "The Straits Times"

AstraZeneca aims to nearly double sales to $107.8 billion by 2030 (The Straits Times)

The drugmaker will launch 20 new medicines by the end of the decade. Read more at straitstimes.com.

Post cover
Image courtesy of "INQUIRER.net"

AstraZeneca to build $1.5-B manufacturing facility in Singapore (INQUIRER.net)

Global biopharmaceutical company AstraZeneca intends to build a US$1.5 billion (S$2 billion) manufacturing facility in Singapore.

Post cover
Image courtesy of "FinanceAsia"

AstraZeneca invests $1.5bn in Singapore facility for next-generation ... (FinanceAsia)

The manufacturing facility, supported by Singapore's Economic Development Board, is for antibody drug conjugates, and will be designed to be "zero carbon" ...

Post cover
Image courtesy of "Financial Times"

AstraZeneca targets $80bn revenue by 2030 (Financial Times)

AstraZeneca has announced plans to almost double revenue to $80bn by 2030, as chief executive Pascal Soriot prepares for an investor update viewed ...

Post cover
Image courtesy of "The Guardian"

AstraZeneca aims to nearly double revenues to $80bn by 2030 (The Guardian)

UK's biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade.

Post cover
Image courtesy of "STAT"

At a flashy new research hub, AstraZeneca lays out ambitious ... (STAT)

The company is seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Post cover
Image courtesy of "Contract Pharma"

AstraZeneca to Build ADC Manufacturing Facility in Singapore (Contract Pharma)

Will be AstraZeneca's first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale.

AstraZeneca sets sights on $80B in revenue by 2030 (BioPharma Dive)

A decade ago, as British drugmaker AstraZeneca fought off a hostile takeover bid by Pfizer, CEO Pascal Soriot made a big promise: The company, he said, would ...

Post cover
Image courtesy of "BioPharma-Reporter.com"

AstraZeneca's fasenra asthma drug shows promise for COPD ... (BioPharma-Reporter.com)

AstraZeneca's Fasenra (benralizumab) has recently been approved by the FDA for treating severe asthma in children aged 6 to 11 with the eosinophilic ...

Post cover
Image courtesy of "The Star Online"

AstraZeneca to build plant in Singapore (The Star Online)

Global biopharmaceutical company AstraZeneca intends to build a US$1.5bil manufacturing facility in Singapore, the company says.

Post cover
Image courtesy of "BioSpace"

AstraZeneca Sets $80B Revenue Target, Goal of 20 New Drugs by ... (BioSpace)

AstraZeneca on Tuesday laid out an ambitious plan to boost growth in its existing oncology, biopharma and rare disease portfolios, as well as launch 20 new ...

Post cover
Image courtesy of "Singapore Business Review"

AstraZeneca plans $2.02b ADC manufacturing facility in Singapore (Singapore Business Review)

The manufacturing process involves antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of ...

Explore the last week